HYPHENS PHARMA INTL LIMITED (1J5) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of HYPHENS PHARMA INTL LIMITED stock S$0.40, price S$0.35, upside +14.3%, quality 73 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
HYPHENS PHARMA INTL LIMITED
1J5 · SGSolid company and rising price, but only slightly cheap (13% below fair value): meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range 0.2057 SGD – 0.3750 SGD · fair‑value band 0.3000 SGD – 0.5000 SGD · the 0.3500 SGD price screens below the 0.4000 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether HYPHENS PHARMA INTL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.
Show moreShow less
It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments.
The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries.
This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics.
Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals.
The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore.
The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.
Stock analysis
HYPHENS PHARMA INTL LIMITED (1J5) currently trades at 0.3500 SGD, while our model-based Fair Value estimate is 0.4000 SGD, implying the stock looks roughly 13% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.8100 SGD per share, and 17 of the 26 models we run sit above the 0.3500 SGD price.
Bear case: the Asset-Based group reads lowest at 0.1400 SGD, and 9 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.3000 SGD (bear) to 0.5000 SGD (bull), the price of 0.3500 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
HYPHENS PHARMA INTL LIMITED reported revenue of 177M SGD in FY2025 versus 126M SGD in FY2021, a compound +8.9%/yr. Reported net income was 5.8M SGD in FY2025, compounding −3.9%/yr from FY2021.
Key figures
Market cap 108M SGD (≈ $83.9M) Micro · P/E ratio 11.7 · P/S ratio 0.61 · EPS (TTM) 0.0300 SGD · Dividend yield 4.3% · Net margin 4.8% · Return on equity 13.0% · Return on assets (EBIT) 11.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 36% fair-value upside, at 14%, 1J5 screens richer than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 1J5, get fair value alerts →
Compare HYPHENS PHARMA INTL LIMITED with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks
Valuation Multiplesvs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Consumer Staples sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Piotroski F-Score screener with fair value
- Valuation of the Singapore market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Sinopharm Group 1099 | HK$16.96 | HK$50.88 | +200% | vs 1J5 |
| Jointown Pharmaceutical Group 600998 | ¥5.25 | ¥11.56 | +120% | vs 1J5 |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.51 | ¥35.78 | +117% | vs 1J5 |
| China National Medicines Corporation 600511 | ¥28.87 | ¥58.47 | +103% | vs 1J5 |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥19.59 | ¥26.64 | +36% | vs 1J5 |
| Cencora, Inc COR | $359.03 | $341.58 | −5% | vs 1J5 |
| Henry Schein, Inc HSIC | $86.22 | $78.69 | −9% | vs 1J5 |
| McKesson Corporation MCK | $1,103 | $822.74 | −25% | vs 1J5 |
| Galenica AG GALE | CHF 91.40 | CHF 61.79 | −32% | vs 1J5 |
| Cardinal Health, Inc CAH | $281.10 | $163.14 | −42% | vs 1J5 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is HYPHENS PHARMA INTL LIMITED (1J5) overvalued or undervalued?
What is the fair value of 1J5?
What is the quality score of 1J5?
What is the price target for HYPHENS PHARMA INTL LIMITED (1J5)?
What is the HYPHENS PHARMA INTL LIMITED stock forecast for 2026?
What is the revenue of HYPHENS PHARMA INTL LIMITED (1J5)?
Does HYPHENS PHARMA INTL LIMITED pay a dividend?
How much is the dividend of HYPHENS PHARMA INTL LIMITED (1J5) and when is the ex-dividend date?
What growth is priced into HYPHENS PHARMA INTL LIMITED (1J5)?
What discount rate (WACC) does the fair value of 1J5 use?
What is a reverse DCF?
How much growth has HYPHENS PHARMA INTL LIMITED (1J5) delivered so far?
How fast is the sector of HYPHENS PHARMA INTL LIMITED (1J5) growing?
What is the free cash flow yield of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the intrinsic value of HYPHENS PHARMA INTL LIMITED (1J5)?
Is HYPHENS PHARMA INTL LIMITED stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 1J5?
How much is HYPHENS PHARMA INTL LIMITED worth?
What do the bullish and bearish scenarios say about 1J5?
What is the P/E ratio of 1J5?
What is the PEG ratio of 1J5?
How solid is the balance sheet of HYPHENS PHARMA INTL LIMITED (1J5)?
How far is 1J5 from its 52-week high?
Which stocks are comparable to HYPHENS PHARMA INTL LIMITED?
Is HYPHENS PHARMA INTL LIMITED stock attractive at the current price?
How is the fair value of 1J5 calculated?
Is it still worth investing in stocks now?
What is the share price of HYPHENS PHARMA INTL LIMITED (1J5)?
What should I pay attention to with HYPHENS PHARMA INTL LIMITED right now?
Key figures of HYPHENS PHARMA INTL LIMITED
How large is the market capitalisation of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the P/S ratio of HYPHENS PHARMA INTL LIMITED (1J5)?
What are the earnings per share of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the dividend yield of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the net margin of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the return on equity of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the EBIT return on assets of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the operating margin of HYPHENS PHARMA INTL LIMITED (1J5)?
How fast is revenue growing at HYPHENS PHARMA INTL LIMITED (1J5)?
How fast are earnings growing at HYPHENS PHARMA INTL LIMITED (1J5)?
Watch HYPHENS PHARMA INTL LIMITED in the live analysis
One click puts HYPHENS PHARMA INTL LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.